15289-s-bos

7 115 | Latest developments in the treatment of lipoprotein (a) References 1. Mulder JERvLaMT. Lipoproteïne(a) als cardiovasculaire risicofactor. NTVG 2011; Ned Tijdschr Geneeskd. 2011;155:A3582. 2. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31:2844-2853. 3. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. Journal of internal medicine 2013; 273:6-30. 4. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA : the journal of the American Medical Association 2009; 301:2331-2339. 5. Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA : the journal of the American Medical Association 2009; 302:412- 423. 6. Thanassoulis G, Campbell CY, Owens DS et al. Genetic associations with valvular calcification and aortic stenosis. The New England journal of medicine 2013; 368:503-512. 7. Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. The New England journal of medicine 2009; 361:2518-2528. 8. Lian XQ, Zhao D, Zhu M et al. The influence of regular walking at different times of day on blood lipids and inflammatory markers in sedentary patients with coronary artery disease. Prev Med 2014; 58:64-69. 9. Kadoglou NPE, Fotiadis G, Athanasiadou Z et al. The effects of resistance training on ApoB/ApoA-I ratio, Lp(a) and inflammatory markers in patients with type 2 diabetes. Endocrine 2012; 42:561-569. 10. Rouhani MH, Kelishadi R, Hashemipour M et al. The effect of an energy restricted low glycemic index diet on blood lipids, apolipoproteins and lipoprotein (a) among adolescent girls with excess weight: A randomized clinical trial. Lipids 2013; 48:1197-1205. 11. Langsted A, Kamstrup PR, Nordestgaard BG. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis 2014; 234:95-101. 12. Howard BV, Rossouw JE. Estrogens and cardiovascular disease risk revisited: the Women’s Health Initiative. Curr Opin Lipidology 2013; 24:493-499. 13. Wasan KM, Goss PE, Pritchard PH et al. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: An NCIC CTG MA.17 sub-study. Breast Cancer Res Treat 2012; 136:769-776. 14. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 2013; 62:479-491. 15. Shoemaker TJ, Kono T, Mariash CN, Evans-Molina C. Thyroid hormone analogues for the treatment of metabolic disorders: New potential for unmet clinical needs? Endocr Pract 2012; 18:954-964. 16. Pramfalk C, Pedrelli M, Parini P. Role of thyroid receptor beta in lipid metabolism. Biochim Biophys Acta 2011; 1812:929-937. 17. Sjouke B, Langslet G, Ceska R et al. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol 2014; 2:455-463. 18. Tsimikas S, Witztum JL, Miller ER et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110:1406-1412. 19. Khera AV, Everett BM, Caulfield MP et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 2014; 129:635-642. 20. Kei A, Liberopoulos E, Tellis K et al. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: A randomized pilot trial. Eur J Clin Invest 2013; 43:698-707. 21. Kim SH, Kim MK, Seo HS et al. Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: A randomized, double-blind, multicenter phase III trial. Clin Ther 2013; 35:1350-1360.e1351.